Kusenda J, Babusíková O
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Neoplasma. 2004;51(2):97-102.
Presented study analyzed the immunophenotypic characteristics and antigen density of peripheral blood (PB) and bone marrow (BM) cells of 23 patients with B-chronic lymphocytic leukemia (B-CLL) and 10 control subjects using flow cytometry. The patients were subclassified into two groups. Group I formed 13 patients with B-CLL at the time of diagnosis and group II 10 patients with B-CLL after the therapy but not in remission. For definition of B-CLL cells we used immunological marker analysis of surface markers characteristic for B-CLL pattern: CD5, CD19, CD20, CD23 and HLA DR and enumeration of fluorescence intensity of these markers given by molecular equivalent of soluble fluorochrome--MESF. In group II of B-CLL patients, who were already treated, in PB and BM somehow lower MESF values for CD19, CD20 and CD23 markers and higher MESF values for CD5 marker (in PB and BM) than in group I patients have been detected. The MESF level of HLA DR marker was little higher in group II than in group I B-CLL patients. However in PB and BM the percentage expression of HLA DR and CD19 markers in both patients groups was approximately the same. The values of HLA DR, CD19, CD20, CD23 and CD5 markers (% expression and MESF values) in both patients groups with B-CLL were significantly higher versus controls (p<0.001 resp. p<0.01) even in PB and BM. In conclusion, in our study we observed that the patients with B-CLL after therapy (group II) had similar or a little smaller (except CD5) but nonsignificantly decreased expression level of markers characteristic for B-CLL, but the MESF values of some of them (CD19, CD23) were significantly (p<0.05) decreased when compared with untreated B-CLL patients (group I). The determination of antigen density (MESF values) may be an important marker to characterize the leukemic cells. Our results showed that chemotherapy did not influence in a significant level the antigen modulation of B-CLL cells, however, could influence MESF values of some characteristic markers. Quantitative analysis of some markers in B-CLL cells seems to offer valuable information concerning possible influence of some chemotherapeutics on antigen equipment of leukemic cells.
本研究采用流式细胞术分析了23例B细胞慢性淋巴细胞白血病(B-CLL)患者和10例对照者外周血(PB)及骨髓(BM)细胞的免疫表型特征和抗原密度。患者被分为两组。第一组为13例诊断时的B-CLL患者,第二组为10例治疗后未缓解的B-CLL患者。对于B-CLL细胞的定义,我们采用了对B-CLL模式特征性表面标志物的免疫标记分析:CD5、CD19、CD20、CD23和HLA DR,并通过可溶性荧光染料分子当量——MESF来计数这些标志物的荧光强度。在已经接受治疗的B-CLL患者第二组中,与第一组患者相比,PB和BM中CD19、CD20和CD23标志物的MESF值有所降低,而CD5标志物(PB和BM中)的MESF值升高。HLA DR标志物的MESF水平在第二组中略高于第一组B-CLL患者。然而,PB和BM中两组患者HLA DR和CD19标志物的表达百分比大致相同。即使在PB和BM中两组B-CLL患者的HLA DR、CD19、CD20、CD23和CD5标志物的值(%表达和MESF值)也显著高于对照组(分别为p<0.001和p<0.01)。总之,在我们的研究中,我们观察到治疗后的B-CLL患者(第二组)具有相似或略小(CD5除外)但无显著降低的B-CLL特征性标志物表达水平,但与未治疗的B-CLL患者(第一组)相比,其中一些标志物(CD19、CD23)的MESF值显著降低(p<0.05)。抗原密度(MESF值)的测定可能是表征白血病细胞的一个重要标志物。我们的结果表明,化疗并未显著影响B-CLL细胞的抗原调节,然而,可能会影响一些特征性标志物的MESF值。对B-CLL细胞中一些标志物的定量分析似乎提供了有关某些化疗药物对白血病细胞抗原装备可能影响的有价值信息。